Arcellx (NASDAQ:ACLX) Lowered to “Hold” Rating by Leerink Partners

Leerink Partners lowered shares of Arcellx (NASDAQ:ACLX) from a strong-buy rating to a hold rating in a research report released on Monday,Zacks.com reports.

A number of other analysts have also issued reports on ACLX. Guggenheim reaffirmed a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Canaccord Genuity Group set a $115.00 price objective on Arcellx in a research report on Monday. HC Wainwright cut Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 target price for the company. in a research report on Monday. Stifel Nicolaus reissued a “hold” rating and issued a $115.00 price target (down from $127.00) on shares of Arcellx in a report on Monday. Finally, Evercore set a $115.00 price objective on shares of Arcellx in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $111.64.

Arcellx Price Performance

Shares of NASDAQ:ACLX opened at $113.71 on Monday. The stock has a market capitalization of $6.57 billion, a P/E ratio of -28.93 and a beta of 0.36. The business has a 50-day moving average of $68.84 and a two-hundred day moving average of $75.38. Arcellx has a fifty-two week low of $47.86 and a fifty-two week high of $114.26.

Insider Transactions at Arcellx

In other Arcellx news, insider Christopher Heery sold 7,437 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total value of $487,197.87. Following the completion of the sale, the insider directly owned 29,631 shares in the company, valued at $1,941,126.81. This represents a 20.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 19,450 shares of company stock valued at $1,283,477 over the last quarter. 8.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arcellx

Several hedge funds and other institutional investors have recently made changes to their positions in the company. MAI Capital Management bought a new stake in shares of Arcellx in the third quarter worth $26,000. CWM LLC grew its position in shares of Arcellx by 267.0% during the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock valued at $28,000 after acquiring an additional 251 shares during the period. State of Wyoming purchased a new position in Arcellx in the 2nd quarter valued at approximately $28,000. Ramirez Asset Management Inc. purchased a new position in Arcellx during the 3rd quarter valued at about $41,000. Finally, Abich Financial Wealth Management LLC bought a new stake in Arcellx during the third quarter valued at $62,000. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Arcellx

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for up to $7.8 billion — deal consideration is $115.00 per share in cash plus a contingent value right (CVR) worth $5.00 if milestones are met; the announcement is the proximate cause of the stock’s big jump. Reuters: Gilead to acquire Arcellx
• Positive Sentiment: Market reaction: shares surged strongly in premarket trading on the acquisition — investors priced the takeover premium into ACLX ahead of regulatory and shareholder reviews. Investopedia: Why ACLX jumped
• Neutral Sentiment: HC Wainwright published bullish long-term EPS projections (FY2030 EPS of $4.95) and has a Neutral rating with a $115 price objective — signals some analysts see material upside longer term, but currently assigns a conservative near-term stance. MarketBeat: HC Wainwright note
• Neutral Sentiment: Robert W. Baird changed its rating to Hold while nudging its target to $115 (from $106) — this reflects mixed analyst views: higher valuation assumptions but a more cautious recommendation. Benzinga: Baird note
• Negative Sentiment: Widespread analyst downgrades: several firms (Needham, Wells Fargo, Truist, Canaccord, Citigroup, Evercore, Leerink/SvB) moved ACLX to Hold/Equal Weight from Buy/Strong Buy — these downgrades reduce the buy-side conviction and can apply near-term selling pressure. Zacks/Benzinga aggregation of downgrades
• Negative Sentiment: Multiple shareholder law firms and investor alerts (Kahn Swick & Foti, Ademi, Halper Sadeh, M&A Class Action Firm, others) are investigating whether Arcellx shareholders are receiving a fair price and whether the sale process was adequate — ongoing litigation risk and potential deal scrutiny may weigh on sentiment and could complicate closing. BusinessWire: Investor alert on Arcellx sale

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.